A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC

Phase 4

Terminated

• Conditions: Esophageal Neoplasms
• Interventions: Drug: Sodium Glycididazole

• Registration Number: NCT02721576
• Lead Sponsor: Shandong Cancer Hospital and Institute

Brief Summary

This is a perspective, multicenter,single arm, open study to evaluate the efficacy and safety of treatment with CMNa combined with concurrent chemoradiotherapy in patients with locally recurrent squamous cell esophageal carcinoma . Analyses of primary objective (ORR) will be done as defined in the protocol.

Detailed Description

The primary end point of this study is objective response rate.The secondary end point is OS, PFS and the safety of drug. The primary hypothesis is the CMNa will improve ORR and thus improve OS, PFS. Assuming bilateral a=0.05, statistical power of 80%. The total sample size is 40 cases.

Study Timeline

• Study First Submitted: 2016-03-09
• Study First Submitted QC: 2016-03-22
• Study First Posted: 2016-03-29
• Study Start: 2016-07-05
• Primary Completion: 2018-06-30
• Study Completion: 2018-07-30
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-10
• Last Update Posted: 2019-10-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Signed written informed consent prior to study entry
2. Patients with recurrent ESCC after radiotherapy, confirmed by imaging and pathology or cytology;
3. Capable for chemo-radiotherapy;
4. The existence of measurable lesions;
5. ECOG PS of 0 or 1
6. Possible semi-liquid diet;
7. Expected lifetime≥3 months
8. normal bone marrow reserve: ANC count ≥1500/mm3;platelet count ≥100,000/ mm3,hemoglobin≥9g/dl
9. normal hepatic function:bilirubin level ≤1.5×ULN;AST/ALT≤1.5×ULN
10. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance ≥60ml/min
11. Normal cardiac function
12. Subjects tumor tissue available for the relevant biomarker detection
13. Clinical stage: No distant metastasis

Exclusion Criteria

1. Female subject who is during pregnancy or lactation, and the subject who have fertility don't take effective contraception during study
2. Any mental illness or nervous system lesions or can't tell treatment response clearly (such as cerebrovascular accident sequelae)
3. Any serious uncontrolled disease and infection, such as severe heart, liver, kidney diseases or diabetes, can't complete the treatment plan
4. Patients who have other malignant lesions, except curable skin cancer (non-melanoma skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years
5. Patients with distant metastasis.
6. Patients who have obvious esophageal ulcers or have above moderate pains in chest-back or have symptoms of esophageal perforation
7. received anti-cancer treatment of esophageal cancer before the group, including surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is greater than or equal to two cycles)
8. Not esophageal squamous carcinoma confirmed by pathology or cytology
9. History of active hepatitis
10. Unable to comprehend the study requirement or who are not likely to comply with the study requirements
11. Significant disease which, in the investigator's opinion, would exclude the patient from the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sodium Glycididazole	Sodium Glycididazole	Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle. OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T\>40Gy/20f,week 1-\>5

Primary Outcome Measures

Name	Time	Method
Objective response rate	up to 3 month

Secondary Outcome Measures

Name	Time	Method
Overall survival	36 months
Progression free survival	36 months

Trial Locations

Locations (9)

Qianfoshan Hospital of Shandong; 🇨🇳 Jinan, Shandong, China

Shandong Cancer Hospital and Institute; 🇨🇳 Jinan, Shandong, China

Jining NO.1 People's Hospital; 🇨🇳 Jining, Shandong, China

Liaocheng People Hospital; 🇨🇳 Liaocheng, Shandong, China

Qingdao Center Medical Group; 🇨🇳 Qingdao, Shandong, China

Rizhao City People 's Hospital; 🇨🇳 Rizhao, Shandong, China

The Fourth People's Hospitalof Zibo; 🇨🇳 Zibo, Shandong, China

Fei Cheng People's Hospital; 🇨🇳 Tai'an, Shandong, China

An Qiu People's Hospital; 🇨🇳 Weifang, Shandong, China